ULTOMIRIS (Alexion Pharmaceuticals Australasia Pty Ltd)
Product name
ULTOMIRIS
Date registered
Evaluation commenced
Decision date
Approval time
232 (255 working days)
Active ingredients
ravulizumab
Registration type
EOI
Indication
ULTOMIRIS is now also indicated for the treatment of patients with
- :
- Paroxysmal Nocturnal Haemoglobinuria (PNH)
- Atypical Haemolytic Uraemic Syndrome (aHUS)